skip to main content
Show Results with: Show Results with:

RCT: Dasotraline shows promise as new ADHD medication

The Brown University child & adolescent psychopharmacology update: the premier monthly forum about the use of psychotropic medications in the young. Volume 21:Issue 5 (2019); pp 1-3 -- Wiley Subscription Services, Inc

Online access

  • Title:
    RCT: Dasotraline shows promise as new ADHD medication
  • Found In: The Brown University child & adolescent psychopharmacology update: the premier monthly forum about the use of psychotropic medications in the young. Volume 21:Issue 5 (2019); pp 1-3
  • Journal Title: The Brown University child & adolescent psychopharmacology update: the premier monthly forum about the use of psychotropic medications in the young
  • Subjects: Pediatric psychopharmacology--Periodicals; Psychopharmacology--Periodicals; Dewey: 615.78083
  • Rights: legaldeposit
  • Publication Details: Wiley Subscription Services, Inc
  • Abstract: Abstract :

    Treatment with investigational drug dasotraline improved symptoms of attention‐deficit/hyperactivity disorder (ADHD) in a placebo‐controlled study in children age 6–12 years, according to a report published in the Journal of Child and Adolescent Psychopharmacology in March. Four milligrams a day significantly improved attention and hyperactivity, with the most frequently reported adverse events being insomnia, decreased appetite, decreased weight, and irritability.


  • Identifier: System Number: LDEAvdc_100081168131.0x000001; Journal ISSN: 1527-8395; 10.1002/cpu.30392
  • Publication Date: 2019
  • Physical Description: Electronic
  • Shelfmark(s): ELD Digital store

Searching Remote Databases, Please Wait